TABLE 4.
Follow-up of the patients with primary HIV-1 infection
Patient no.a | Follow-up | Proviral HIV-1 DNA (copies/106 PBMC) at:
|
QCVc (IU/106 PBMC) | Plasma HIV-1 RNA (copies/ml) | No. of cells/mm3
|
||
---|---|---|---|---|---|---|---|
60°C | 65°Cb | CD4+ | CD8+ | ||||
1 | D0 | 1,342 | 1,025 | 32.9 | >750,000 | 621 | 1,454 |
M1 | 362 | 449 | <0.1 | 1,208 | 620 | 456 | |
M6 | 146 | 116 | <0.1 | 72 | 501 | 571 | |
M12 | 44 | 25 | <0.1 | <50 | 645 | 685 | |
2 | D0 | 923 | 0 | 166.3 | >750,000 | 813 | 745 |
M1 | 212 | 0 | <0.1 | NDd | 859 | 756 | |
M6 | 48 | 0 | <0.1 | <50 | 704 | 558 | |
M12 | 21 | 0 | <0.1 | <50 | 887 | 684 | |
3 | D0 | 676 | 331 | 2.9 | 57,161 | 417 | 1,124 |
M1 | 288 | 355 | 3.1 | 324 | 463 | 748 | |
M6 | 147 | 91 | <0.1 | <50 | 658 | 559 | |
M12 | 0 | <10 | <0.1 | <50 | 650 | 619 | |
4 | D0 | 436 | 105 | 24.2 | 52,674 | 438 | 1,826 |
M1 | 369 | 27 | 0.6 | 940 | 659 | 1,070 | |
M6 | 175 | 9 | <0.1 | <50 | 828 | 1,118 | |
M12 | 72 | 10 | <0.1 | <50 | 758 | 778 | |
5 | D0 | 266 | <10 | ND | 128,100 | 663 | 743 |
M4 | 0 | <10 | <0.1 | ND | 831 | 648 | |
M6 | 20 | <10 | <0.1 | 105 | 985 | 788 | |
M12 | <10 | 0 | <0.1 | <50 | 1,216 | 998 | |
6 | D0 | 259 | 0 | 32.9 | 404,906 | 258 | 1,632 |
M1 | 210 | 0 | 2.1 | 11,251 | 604 | 1,203 | |
M6 | 159 | 0 | <0.1 | <50 | 711 | 979 | |
M12 | 38 | 0 | <0.1 | <50 | 760 | 925 | |
7 | D0 | 155 | <10 | 16.2 | 181,988 | 502 | 441 |
M1 | 32 | <10 | 0.3 | 3,552 | 740 | 332 | |
M6 | 12 | <10 | <0.1 | <50 | 738 | 258 | |
M12 | <10 | 19 | <0.1 | <50 | 1,003 | 404 | |
8 | D0 | 105 | 26 | ND | 46,029 | ND | ND |
M1 | 30 | <10 | <0.1 | 284 | 485 | 798 | |
M6 | <10 | <10 | <0.1 | <50 | 546 | 693 | |
M12 | 0 | <10 | <0.1 | <50 | 637 | 986 | |
9 | D0 | 10 | <10 | 2.5 | 89,049 | 367 | 454 |
M3 | 0 | <10 | <0.1 | <50 | 177 | 130 | |
M6 | <10 | <10 | <0.1 | <50 | 582 | 466 | |
M15 | 0 | <10 | <0.1 | <50 | 590 | 407 | |
10 | D0 | 9,182 | ND | 35.0 | >750,000 | 261 | 1,783 |
M12 | 53 | ND | <0.1 | <50 | 508 | 381 | |
11 | D0 | 1,168 | ND | 32.9 | 57,480 | 543 | 625 |
M12 | 358 | ND | <0.1 | 178 | 746 | 723 | |
12 | D0 | 963 | ND | 24.2 | 100,740 | 306 | 1,193 |
M12 | 245 | ND | <0.1 | <50 | 454 | 861 | |
13 | D0 | 707 | ND | 9.1 | 139,120 | 534 | 1,595 |
M12 | 108 | ND | <0.1 | 75 | 661 | 610 | |
14 | D0 | 466 | ND | 17.0 | 178,000 | 238 | 938 |
M12 | 10 | ND | <0.1 | <50 | 188 | 776 | |
15 | D0 | 143 | ND | 24.2 | 254,400 | 600 | 3,186 |
M12 | 38 | ND | <0.1 | <200 | 1,113 | 1,089 | |
16 | D0 | 42 | ND | 24.0 | 28,960 | 270 | 450 |
M12 | 16 | ND | <0.1 | <50 | 505 | 355 |
Patients 1 to 9 were treated with lamivudine, stavudine and indinavir and patients 10 to 16 were treated with zidovudine, lamivudine and didanosine and monitored as described in Materials and Methods.
For patients 1 to 9, proviral HIV-1 DNA was also quantified with a PCR annealing temperature of 65°C, instead of 60°C.
QCV, quantitative cellular viremia.
ND, not determined.